ASCO 2022 on a Regional Subgroup Analysis of the Phase 3 TOPAZ-1 Study of Durvalumab + Gemcitabine & Cisplatin in Advanced Biliary Tract Cancer

153 views
June 15, 2022
Comments 0
Login to view comments. Click here to Login